Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04410796
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- NCT04410796 ↗
- Recruiting
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built an HCP commentary report on NCT04410796 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04410796 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Osimertinib; Carboplatin; Pemetrexed
- Arms
- Osimertinib alone · Experimental
- Osimertinib plus Carboplatin and Pemetrexed · Experimental
- Enrollment
- 571 (estimated)
- Primary outcomes
- Determine the progression-free survival
- Sponsor
- Memorial Sloan Kettering Cancer Center with AstraZeneca, Guardant Health, Inc.
- Start
- May 28, 2020
- Primary completion
- May 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04410796 · updated Sep 11, 2026